Phase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma

被引：0
|
作者：
Wen, P. Y. [1 ]
Shih, K. [2 ]
Schiff, D. [3 ]
Brachmann, R. [4 ]
Weitzman, R. [4 ]
Cloughesy, T. [5 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Sarah Cannon Res Insititute, Neurooncol, Nashville, TN USA
[3] Univ Virginia Hlth Syst, Neurol, Charlottesville, VA USA
[4] BeiGene USA Inc, Clin Dev, Emeryville, CA USA
[5] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS
    Zakharia, Yousef
    Munn, David
    Link, Charles
    Vahanian, Nicholas
    Kennedy, Eugene
    NEURO-ONCOLOGY, 2016, 18 : 13 - 14
  • [22] TROTABRESIB (CC-90010) IN COMBINATION WITH CONCOMITANT TEMOZOLOMIDE PLUS RADIOTHERAPY AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: UPDATED RESULTS FROM A PHASE 1B/2 STUDY
    Vieito, Maria
    Sepulveda, Juan Manuel
    Moreno, Victor
    de Vos, Filip
    Geurts, Marjolein
    Lorenzi, Elena
    Macchini, Marina
    van den Bent, Martin
    Del Conte, Gianluca
    Martin-Soberon, Maria Cruz
    Brandal, Petter
    Martinez Garcia, Maria
    Amoroso, Barbara
    Sanchez-Perez, Tania
    Zuraek, Marlene
    Hanna, Bishoy
    Filvaroff, Ellen
    Chang, Henry
    Parro, Marina Arias
    Wei, Xin
    Liu, Yu
    Nikolova, Zariana
    Simonelli, Matteo
    NEURO-ONCOLOGY, 2022, 24 : 75 - 75
  • [23] Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
    Sahai, Vaibhav
    Zhen, David Bing
    Crysler, Oxana V.
    Beg, Shaalan Shaalan
    Enzler, Thomas
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Colman, Howard
    Raizer, Jeffrey
    Walbert, Tobias
    Plotkin, Scott
    Chamberlain, Marc
    Wong, Eric
    Puduvalli, Vinay
    Reardon, David
    Iwamoto, Fabio
    Johnson, Brett
    Sonty, Karthik
    Welbourn, Bill
    Karlin, David
    Pelayo, Michael
    Hutchinson, Marguerite
    Hsu, Henry
    NEURO-ONCOLOGY, 2016, 18 : 6 - 6
  • [25] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
    Brandes, A. A.
    Tosoni, A.
    Cavallo, G.
    Bertorelle, R.
    Gioia, V.
    Franceschi, E.
    Biscuola, M.
    Blatt, V.
    Crino, L.
    Ermani, M.
    BRITISH JOURNAL OF CANCER, 2006, 95 (09) : 1155 - 1160
  • [26] Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
    A A Brandes
    A Tosoni
    G Cavallo
    R Bertorelle
    V Gioia
    E Franceschi
    M Biscuola
    V Blatt
    L Crinò
    M Ermani
    British Journal of Cancer, 2006, 95 : 1155 - 1160
  • [27] New combination therapies with subcutaneous epcoritamab in first-line therapy and in relapsed non-Hodgkin lymphoma. A phase 1b/2 multicenter, open-label study to assess safety, tolerability, and efficacy
    Duell, J.
    Skarbnik, A. P.
    Avivi, I
    Brody, J.
    Yoon, D. H.
    Elliott, B. M.
    Siddani, S. R.
    Bai, Y.
    Parikh, A.
    Seliem, M. M.
    Dinh, M. H.
    Sehn, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 196 - 196
  • [28] PHASE 1B STUDY OF A NOVEL ORAL PPAR-GAMMA AGONIST, EFATUTAZONE IN COMBINATION WITH FOLFIRI IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER WHO FAILED THE FIRST-LINE THERAPY
    Yoshino, T.
    Yuki, S.
    Yamazaki, K.
    Machida, N.
    Komatsu, Y.
    Oyama, R.
    Yachi, Y.
    Onuma, H.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 201 - 201
  • [29] SAFETY RUN-IN RESULTS OF A PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO; aPDL1) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    O'Brien, Barbara
    Harrison, Rebecca
    Yung, W. K. Alfred
    Penas-Prado, Marta
    de Groot, John
    NEURO-ONCOLOGY, 2018, 20 : 9 - 10
  • [30] Phase 1/2 Study of Pepinemab in Combination with Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84)
    Fisher, T. L.
    Evans, E. E.
    Mallow, C.
    Foster, A.
    Boise, M.
    Smith, E.
    Leonard, J. E.
    Chaney, M.
    Beck, J. T.
    Hager, S.
    Saba, N. F.
    Steuer, C.
    Adkins, D.
    Burtness, B.
    Zauderer, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E36 - E36
12345